These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19377283)

  • 1. Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens.
    Gil J; Betancourt LZ; Sardiñas G; Yero D; Niebla O; Delgado M; García D; Pajón R; Sánchez A; González LJ; Padrón G; Campa C; Sotolongo F; Barberó R; Guillén G; Herrera L; Besada V
    Hum Vaccin; 2009 May; 5(5):347-56. PubMed ID: 19377283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine.
    Dick LW; Mehl JT; Loughney JW; Mach A; Rustandi RR; Ha S; Zhang L; Przysiecki CT; Dieter L; Hoang VM
    Hum Vaccin Immunother; 2015; 11(6):1518-25. PubMed ID: 25997113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
    Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R
    Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media.
    Tsolakos N; Lie K; Bolstad K; Maslen S; Kristiansen PA; Høiby EA; Wallington A; Vipond C; Skehel M; Tang CM; Feavers IM; Wedege E; Wheeler JX
    Vaccine; 2010 Apr; 28(18):3211-8. PubMed ID: 20188677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.
    Masforrol Y; Gil J; García D; Noda J; Ramos Y; Betancourt L; Guirola O; González S; Acevedo B; Besada V; Reyes O; González LJ
    Hum Vaccin Immunother; 2017 Nov; 13(11):2548-2560. PubMed ID: 29083947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.
    Vipond C; Suker J; Jones C; Tang C; Feavers IM; Wheeler JX
    Proteomics; 2006 Jun; 6(11):3400-13. PubMed ID: 16645985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.
    Williams JN; Weynants V; Poolman JT; Heckels JE; Christodoulides M
    Vaccine; 2014 Mar; 32(11):1280-6. PubMed ID: 24486354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.
    Williams JN; Skipp PJ; Humphries HE; Christodoulides M; O'Connor CD; Heckels JE
    Infect Immun; 2007 Mar; 75(3):1364-72. PubMed ID: 17158897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.
    Vaughan TE; Skipp PJ; O'Connor CD; Hudson MJ; Vipond R; Elmore MJ; Gorringe AR
    Vaccine; 2006 Jun; 24(25):5277-93. PubMed ID: 16682101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality by design approach in the development of an ultra-high-performance liquid chromatography method for Bexsero meningococcal group B vaccine.
    Nompari L; Orlandini S; Pasquini B; Campa C; Rovini M; Del Bubba M; Furlanetto S
    Talanta; 2018 Feb; 178():552-562. PubMed ID: 29136861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J
    Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
    Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
    Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A
    Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes.
    Pajon R; Yero D; Niebla O; Climent Y; Sardiñas G; García D; Perera Y; Llanes A; Delgado M; Cobas K; Caballero E; Taylor S; Brookes C; Gorringe A
    Vaccine; 2009 Dec; 28(2):532-41. PubMed ID: 19837092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification.
    Zhang L; Wen Z; Lin J; Xu H; Herbert P; Wang XM; Mehl JT; Ahl PL; Dieter L; Russell R; Kosinski MJ; Przysiecki CT
    Vaccine; 2016 Jul; 34(35):4250-4256. PubMed ID: 27269057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.